News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UCB, Inc.'s Xyrem Rejected in EU for Fibromyalgia
March 18, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- UCB has suffered a setback with the news that European regulators have turned down Xyrem as a treatment for fibromyalgia.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson
